Interactive Features

Test Your Knowledge

Quiz: Is Neutropenia a Prognostic Factor for OS in NSCLC?

11/11/2020

True or false: Moderate neutropenia levels predict improved OS in NSCLC after gem-carbo therapy.

True or false: Moderate...

11/11/2020

Oncology

Test Your Knowledge

Quiz: How Have Advances in Lung Cancer Treatment Affected NSCLC Mortality Rates?

09/16/2020

True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.

True or False: Population-based...

09/16/2020

Oncology

Test Your Knowledge

Quiz: How Have Advances in Lung Cancer Treatment Affected NSCLC Mortality Rates?

09/16/2020

True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.

True or False: Population-based...

09/16/2020

Oncology

Test Your Knowledge

Quiz: Was a Liquid Biopsy Tool Recently FDA Approved to Identify ROS-mutated NSCLC?

09/15/2020

True or false: A liquid biopsy companion diagnostic was recently FDA-approved to help identify ROS-mutated NSCLC.

True or false: A liquid biopsy...

09/15/2020

Oncology

Test Your Knowledge

Quiz: Can a Deep Learning Model Predict Therapy Benefit in NSCLC?

08/31/2020

True or False: A deep learning survival neural network model displays potential benefit in prognostic evaluation and treatment recommendations, with respect to lung cancer–specific survival.

True or False: A deep learning...

08/31/2020

Oncology

Test Your Knowledge

Quiz: Tazemetostat Monotherapy for Relapsed/Refractory Malignant Mesothelioma

08/13/2020

True or False: Tazemetostat is well-tolerated and yields anti-tumor activity in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.

True or False: Tazemetostat is...

08/13/2020

Oncology

Test Your Knowledge

Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?

08/06/2020

Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?

Which combination yielded...

08/06/2020

Oncology

Test Your Knowledge

Quiz: Is Nivolumab-Ipilimumab Plus Chemo FDA-Approved for mNSCLC?

07/17/2020

True or false: The FDA approved nivolumab and ipilimumab along with platinum-doublet chemotherapy for the frontline treatment of patients with metastatic or relapsed NSCLC, based on results from the CHECKMATE-9LA trial.

True or false: The FDA approved...

07/17/2020

Oncology

Test Your Knowledge

Quiz: Pembrolizumab Plus Docetaxel for Advanced, Pretreated NSCLC

04/29/2020

True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.

True or False: In a phase 2...

04/29/2020

Oncology

Test Your Knowledge

Quiz: A Potential Combo Therapy for EGFR-Positive, MET-Amplified NSCLC

04/13/2020

True or False: Researchers posit osimertinib plus savolitinib as a potential combo therapy for MET-amplified, EGFR-positive, advanced NSCLC that progressed with EGFR TKIs.

True or False: Researchers posit...

04/13/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology